Business Wire

New Phase 3 STELARA® (ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

Jaa

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3 UNIFI maintenance study. The data showed that a significantly greater proportion of adults with moderate to severe ulcerative colitis (UC) receiving ustekinumab subcutaneous (SC) maintenance therapy were in clinical remission* at Week 44, compared to patients receiving placebo – the study’s primary endpoint.1 Patients receiving ustekinumab SC maintenance therapy had a clinical response 8 weeks after receiving a single intravenous (IV) dose of ustekinumab.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005469/en/

These data were presented as part of a plenary session (Abstract OP37) at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen, Denmark. At the Congress, Janssen also shared a digital oral presentation with additional data from the UNIFI induction study evaluating the effects of ustekinumab on histo-endoscopic mucosal healing (HEMH), a novel, pre-specified endpoint in this programme.

Results from the maintenance phase of the Phase 3 study demonstrated that 44 percent (90 mg every 8 weeks [q8w]) and 38 percent (90 mg every 12 weeks [q12w]) of patients with moderate to severe UC receiving ustekinumab SC injections achieved clinical remission, as defined by the Mayo score, at week 44 (52 weeks after IV induction) compared to 24 percent of patients who received placebo (p<0.001 and p=0.002, respectively).1 These data were included in submissions to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) seeking approval of ustekinumab as a treatment for UC.

“Ulcerative colitis is a disruptive, lifelong and potentially debilitating inflammatory bowel disease; however, it is a condition where remission is possible,” said lead study investigator William Sandborn, MD, Chief, Division of Gastroenterology and Professor of Medicine, University of California, San Diego. “The data suggest the potential of ustekinumab as an effective therapy for helping people living with ulcerative colitis achieve remission, as well as providing other meaningful outcomes, including clinical response, histo-endoscopic improvement and corticosteroid-free remission.”

Major secondary endpoints, including maintenance of clinical response, endoscopic improvement, corticosteroid-free remission and maintenance of clinical remission from baseline, were also achieved in greater proportions of patients receiving ustekinumab q8w and q12w injections versus patients receiving placebo. At week 44:

  • 71 percent of patients receiving ustekinumab q8w and 68 percent of patients receiving ustekinumab q12w maintained clinical response, compared with 44 percent of patients receiving placebo (both p<0.001).1 Clinical response was defined as a decrease from baseline in the Mayo score by ≥30 percent and ≥3 points, with a rectal bleeding sub-score of 0 or 1 or a decrease in the rectal bleeding sub-score ≥1
  • 51 percent of patients receiving ustekinumab q8w and 44 percent of patients receiving ustekinumab q12w achieved endoscopic improvement, compared with 29 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 Endoscopic improvement was defined as a Mayo endoscopy sub-score of 0 (normal mucosa or inactive disease) or 1 (mild disease activity)
  • 42 percent of patients receiving ustekinumab q8w and 38 percent of patients receiving ustekinumab q12w were in clinical remission and were corticosteroid-free, compared with 23 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 The global remission definition was a Mayo score ≤2 points, with no individual sub-score >1

Through to week 44, the proportions of patients with adverse events (AEs), serious AEs, infections and serious infections in the ustekinumab groups were generally comparable to the placebo group. The proportions of patients who discontinued the study agent were lower with ustekinumab q8w and q12w versus placebo. Among the primary population in the maintenance study, no deaths occurred. Two malignancies other than non-melanoma skin cancer (NMSC) (one colon cancer, q8w; one papillary renal cell carcinoma, q12w) were reported. One patient reported NMSC (two squamous cell carcinoma events, q12w).1 Overall, the safety for ustekinumab in UC patients was consistent with the known safety profile of ustekinumab in Crohn’s disease (CD).2

“The UNIFI maintenance data further build the case for ustekinumab as a potential new treatment option for ulcerative colitis and illustrate our ongoing commitment to researching and developing meaningful therapies for people living with inflammatory bowel diseases,” said Scott E. Plevy, M.D., Gastroenterology Disease Area and IL-23 Pathway Leader, Janssen Research & Development, LLC. “Furthermore, we are proud that UNIFI is the first Phase 3 study to report a combined histo-endoscopic endpoint in patients with ulcerative colitis.”

In the abstract (DOP71) presenting the induction study colonic mucosal healing results, patients achieved higher rates of endoscopic improvement, histologic improvement and the combined endpoint of histo-endoscopic mucosal healing (HEMH), versus placebo, 8 weeks after receiving a single IV induction dose of ustekinumab.3 Histo-endoscopic mucosal healing assesses how the colon is responding both histologically and endoscopically to therapy and both have been associated with improved long-term clinical outcomes, such as reduced risk of relapse and need for surgery/hospitalisation, and reduced risk of developing cancer.4

#ENDS#

About the UNIFI trial
UNIFI is a Phase 3 protocol, designed to evaluate the safety and efficacy of ustekinumab induction and maintenance dosing for the treatment of moderate to severe UC in adults who demonstrated an inadequate response to, or were unable to tolerate, conventional (i.e., corticosteroids, immunomodulators) or biologic (i.e., one or more TNF blockers and/or vedolizumab) therapies. Both the induction and maintenance studies are randomised, double-blind, placebo-controlled, parallel group, multicentre studies. The induction study was conducted over a duration of at least 8 weeks for each participant. Participants achieving clinical response in the induction study were eligible for the maintenance study. The maintenance study was 44 weeks in duration. The primary endpoint of the induction study was clinical remission at week 8, and the primary endpoint for the maintenance study was clinical remission at week 44 among responders to a single IV ustekinumab infusion. After completion of the maintenance study, a long-term extension study will follow eligible participants for an additional three years.

About ulcerative colitis
Ulcerative colitis affects up to 2.6 million people in Europe.5 It is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous. Ulcerative colitis is the result of an abnormal response by the body's immune system. Symptoms vary, but may include loose and more urgent bowel movements, persistent diarrhoea, abdominal pain, bloody stool, loss of appetite, weight loss and fatigue.6

About STELARA ® (ustekinumab) 2
In the European Union, ustekinumab is approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen plus ultraviolet A, and is also indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 years and older who are inadequately controlled by or are intolerant to other systemic therapies or phototherapies. In addition, ustekinumab is approved alone or in combination with MTX for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate. In November 2016, the European Commission approved ustekinumab for the treatment of adult patients with moderate to severe CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to ustekinumab. In December 2018, a Group Type II Variation Application to the EMA was submitted, which seeks approval of ustekinumab for the treatment of adults with moderate to severe UC.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/EMEA. Follow us on Twitter: @JanssenEMEA. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

# # #

References
1. W.J Sandborn, B.E Sands, R. Panaccione, et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 resultus from UNIFI [Abstract OP37]. Presented at European Crohn’s and Colitis Organisation (ECCO 2019) 6-9 March, 2019; Copenhagen, Denmark.
2. European Medicines Agency. (2016) Ustekinumab Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed March 2019.
3. K. Li, J.R Friedman, C Marano, et al. Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis [Abstract DOP71]. Presented at European Crohn’s and Colitis Organisation (ECCO 2019) 6-9 March, 2019; Copenhagen, Denmark.
4. GI Health Foundation. What is Mucosal Healing? Available at: http://www.gihealthfoundation.org/GI_news_and_library/library/ppts/IBD/WhatisMucosalHealing.pdf. Accessed March 2019.
5. Ng SC, Shi HY, Underwood FE, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-78.
6. Crohn’s & Colitis Foundation. What is Ulcerative Colitis? Available at: http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/. Accessed March 2019.

*Remission was defined as a Mayo score ≤2 points, with no individual sub-score >1. The Mayo score is designed to measure the severity of UC, giving a score from 0–12 points; a higher score indicates more severe disease activity

Limited Liability Company

Contact information

Media Contact:
Emily Bone
Phone: +44 787-639-4360
ebone1@its.jnj.com

Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955

Lesley Fishman
Phone: +1 732-524-3922

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

PIVOT Fintech Gets Capital Markets Services License From The Monetary Authority Of Singapore25.3.2019 00:30:00 EETTiedote

PIVOT Fintech Pte. Ltd. (“PIVOT”), the digital wealth management technology services venture backed by Pintec Technology Holdings Ltd. (“PINTEC”; NASDAQ: PT) and FWD Group announced today that it has been granted a Capital Markets Services (“CMS”) license by the Monetary Authority of Singapore (MAS). PIVOT’s CMS license, which comes after the recently published MAS Guidelines on the Provision of Digital Advisory Services on 8 October 2018, allows the company to offer AI-driven investment services directly to retail clients. “This significant Singapore milestone marks the start of PIVOT’s ambition to deliver innovative wealth management solutions in Southeast Asia,” said PIVOT CEO Victor Lye, who created PIVOT’s proprietary gamified risk profiling analytics to drive financial inclusiveness. PIVOT’s core shareholder, PINTEC, has proven technology and expertise in delivering AI-driven global asset allocation and money management services to financial institutions in the highly competitive

1.1 Million People Benefit from the UAE-based Big Heart Foundation’s Humanitarian Efforts in 201824.3.2019 22:21:00 EETTiedote

Humanitarian aid worth US$ 15.8 million (AED 58 million) to 1,091,000 million refugees, internally displaced and acutely disadvantaged people in 12 conflict-laden nations worldwide has been offered by The Big Heart Foundation (TBHF), a leading international humanitarian organisation based in Sharjah, UAE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190324005019/en/ (TBHF Graphic) Operating under the leadership of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, UNHCR Eminent Advocate and TBHF Chairperson, the humanitarian non-profit operating out of Sharjah – the third largest emirate in United Arab Emirates (UAE) – has mobilised the funds to support and initiate 20 projects in collaboration with UNHCR, Doctors without Borders (Médecins Sans Frontières) in vital sectors of food security, healthcare and education. Their 2018 efforts spanned 12 countries, namely, Bangladesh, Egypt, Iraq, Jordan, Malaysia, Pakistan, Pal

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 18:55:00 EETTiedote

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 17:29:00 EETTiedote

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of

Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 17:15:00 EETTiedote

Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha

Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation22.3.2019 16:00:00 EETTiedote

Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190322005013/en/ Trueman Man Clinic Network has been successfully completed the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation). The SWITCH Premature Ejaculation Surgery (SWITCH operation) developed in 2010 by Dr. Yang, the chief director of the Trueman Man Clinic Network, can reduce the side effects of penile neurectomy and maintain the stable reduction of the glans sensation. The Trueman Man Clinic Network is the leading hospitals for male enhancement surgeries in Korea consists of 11 clinics, with 16 doctors working. As of 2019, more than 43,000 man clinic surgeries have been performed. (Photo: Business Wire) The Trueman Man Clinic Network is the leading hospitals for m

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme